Linked Life Data

18272023

Source:http://linkedlifedata.com/resource/pubmed/id/18272023

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2008-2-14
pubmed:abstractText
Results of preclinical studies and clinical phase I/II trials suggest that the antisense oligodeoxynucleotide and DNA methyltransferase inhibitor MG98 can safely and effectively lead to reactivation of methylation silence tumor suppressor genes. It is possible that daily or continuous dosing of MG98 might be more active and less toxic than intermittent dosing. Combination of MG98 with other agents having completely different mechanisms of action seems reasonable. One clinical trial now under way is evaluating the use of MG98 in combination with interferon-alpha in patients with advanced renal cell carcinoma (RCC). Because of the current preclinical and clinical evidence, further trials of MG98 as therapy for RCC would be of interest.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1558-7673
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
422-6
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy.
pubmed:affiliation
Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA. ramato@tmh.tmc.edu
pubmed:publicationType
Journal Article, Review